Does the media favor PROK or SRPT?

In the previous week, Sarepta Therapeutics had 10 more articles in the media than ProKidney. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 3 mentions for ProKidney. Sarepta Therapeutics' average media sentiment score of 0.54 beat ProKidney's score of 0.18 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is LKFT or PROK more profitable?

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A ProKidney -10,288.39% N/A -27.39%

Which has higher valuation & earnings, PROK or MESO?

Mesoblast has higher revenue and earnings than ProKidney. Mesoblast is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 536.70 -$68.99M -$0.55 N/A Mesoblast $120.25M 15.36 -$57.50M -$0.28 N/A

Is PROK or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. Company Net Margins Return on Equity Return on Assets ProKidney -10,288.39% N/A -27.39% Mesoblast N/A N/A N/A

Does the media refer more to PROK or MESO?

In the previous week, Mesoblast had 1 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Mesoblast and 3 mentions for ProKidney. Mesoblast's average media sentiment score of 0.31 beat ProKidney's score of 0.18 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, PROK or ZYME?

ProKidney has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 536.70 -$68.99M -$0.55 N/A Zymeworks $37.13M 50.09 -$81.13M -$2.02 N/A

Is PROK or ZYME more profitable?

Zymeworks has a net margin of -405.31% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -10,288.39% N/A -27.39% Zymeworks -405.31% -72.30% -37.18%

Does the media refer more to PROK or ZYME?

In the previous week, Zymeworks had 2 more articles in the media than ProKidney. MarketBeat recorded 5 mentions for Zymeworks and 3 mentions for ProKidney. Zymeworks' average media sentiment score of 0.19 beat ProKidney's score of 0.18 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, XNCR or PROK?

ProKidney has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $104.97M 18.15 -$91.92M -$2.17 N/A ProKidney $890K 536.70 -$68.99M -$0.55 N/A

Is XNCR or PROK more profitable?

Xencor has a net margin of -155.59% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% ProKidney -10,288.39% N/A -27.39%

Does the media prefer XNCR or PROK?

In the previous week, Xencor had 1 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Xencor and 3 mentions for ProKidney. Xencor's average media sentiment score of 0.57 beat ProKidney's score of 0.18 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProKidney (PROK) Competitors

$1.58 -0.01 (-0.32%)

As of 03:23 PM Eastern

Compare

PROK vs. SRPT, LKFT, MESO, ZYME, and XNCR

Should you buy ProKidney stock or one of its competitors? ProKidney's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Lakefront Biotherapeutics American Depositary Shares (LKFT), Mesoblast (MESO), Zymeworks (ZYME), and Xencor (XNCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProKidney compare to Sarepta Therapeutics?

ProKidney (NASDAQ:PROK) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Sarepta Therapeutics has a net margin of -13.48% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

ProKidney has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

ProKidney currently has a consensus target price of $12.00, indicating a potential upside of 659.49%. Sarepta Therapeutics has a consensus target price of $22.71, indicating a potential upside of 29.82%. Given ProKidney's stronger consensus rating and higher possible upside, equities research analysts clearly believe ProKidney is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Sarepta Therapeutics	7 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sarepta Therapeutics had 10 more articles in the media than ProKidney. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 3 mentions for ProKidney. Sarepta Therapeutics' average media sentiment score of 0.54 beat ProKidney's score of 0.18 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ProKidney has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	536.70	-$68.99M	-$0.55	N/A
Sarepta Therapeutics	$2.20B	0.84	-$713.41M	-$2.90	N/A

Summary

ProKidney beats Sarepta Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ProKidney compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
ProKidney	-10,288.39%	N/A	-27.39%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $37.00, suggesting a potential upside of 25.38%. ProKidney has a consensus price target of $12.00, suggesting a potential upside of 659.49%. Given ProKidney's stronger consensus rating and higher probable upside, analysts clearly believe ProKidney is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than ProKidney. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.55	$363.05M	-$1.41	N/A
ProKidney	$890K	536.70	-$68.99M	-$0.55	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for ProKidney. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.74 beat ProKidney's score of 0.18 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ProKidney beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 15 factors compared between the two stocks.

How does ProKidney compare to Mesoblast?

ProKidney (NASDAQ:PROK) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

In the previous week, Mesoblast had 1 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Mesoblast and 3 mentions for ProKidney. Mesoblast's average media sentiment score of 0.31 beat ProKidney's score of 0.18 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has higher revenue and earnings than ProKidney. Mesoblast is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	536.70	-$68.99M	-$0.55	N/A
Mesoblast	$120.25M	15.36	-$57.50M	-$0.28	N/A

51.6% of ProKidney shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mesoblast has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Mesoblast	N/A	N/A	N/A

ProKidney has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

ProKidney currently has a consensus price target of $12.00, suggesting a potential upside of 659.49%. Mesoblast has a consensus price target of $39.00, suggesting a potential upside of 174.26%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Mesoblast beats ProKidney on 9 of the 16 factors compared between the two stocks.

How does ProKidney compare to Zymeworks?

ProKidney (NASDAQ:PROK) and Zymeworks (NASDAQ:ZYME) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Zymeworks had 2 more articles in the media than ProKidney. MarketBeat recorded 5 mentions for Zymeworks and 3 mentions for ProKidney. Zymeworks' average media sentiment score of 0.19 beat ProKidney's score of 0.18 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProKidney has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	536.70	-$68.99M	-$0.55	N/A
Zymeworks	$37.13M	50.09	-$81.13M	-$2.02	N/A

ProKidney presently has a consensus price target of $12.00, indicating a potential upside of 659.49%. Zymeworks has a consensus price target of $40.45, indicating a potential upside of 54.35%. Given ProKidney's higher probable upside, equities research analysts clearly believe ProKidney is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

51.6% of ProKidney shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ProKidney has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Zymeworks has a net margin of -405.31% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Zymeworks	-405.31%	-72.30%	-37.18%

Summary

ProKidney beats Zymeworks on 10 of the 17 factors compared between the two stocks.

How does ProKidney compare to Xencor?

Xencor (NASDAQ:XNCR) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

51.6% of ProKidney shares are held by institutional investors. 5.1% of Xencor shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ProKidney has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$104.97M	18.15	-$91.92M	-$2.17	N/A
ProKidney	$890K	536.70	-$68.99M	-$0.55	N/A

Xencor has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Xencor currently has a consensus target price of $34.00, suggesting a potential upside of 32.66%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 659.49%. Given ProKidney's stronger consensus rating and higher probable upside, analysts plainly believe ProKidney is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Xencor has a net margin of -155.59% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
ProKidney	-10,288.39%	N/A	-27.39%

In the previous week, Xencor had 1 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Xencor and 3 mentions for ProKidney. Xencor's average media sentiment score of 0.57 beat ProKidney's score of 0.18 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Xencor on 10 of the 16 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$476.15M	$3.81B	$7.11B	$13.43B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-2.86	13.40	274.02	26.27
Price / Sales	535.00	1,216.00	595.43	86.00
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	-0.47	16.85	11.17	6.39
Net Income	-$68.99M	-$23.16M	$3.49B	$381.07M
7 Day Performance	-3.37%	-3.62%	-2.08%	-0.41%
1 Month Performance	-21.64%	-11.66%	-6.80%	-4.63%
1 Year Performance	-45.69%	15.17%	5.94%	1.40%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	1.6682 of 5 stars	$1.58 -0.3%	$12.00 +661.9%	-42.3%	$476.15M	$890K	N/A	231
SRPT Sarepta Therapeutics	2.9989 of 5 stars	$18.22 -2.3%	$23.81 +30.7%	-22.7%	$1.97B	$1.97B	N/A	835	News Coverage Analyst Forecast
LKFT Lakefront Biotherapeutics American Depositary Shares	2.602 of 5 stars	$29.65 +0.4%	$37.00 +24.8%	-21.6%	$1.95B	$1.26B	N/A	1,310
MESO Mesoblast	2.2866 of 5 stars	$14.65 -1.5%	$39.00 +166.2%	-22.8%	$1.93B	$120.25M	N/A	108	Gap Down
ZYME Zymeworks	2.4564 of 5 stars	$26.49 -2.6%	$40.45 +52.7%	+54.7%	$1.93B	$105.96M	N/A	264

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. SRPT, LKFT, MESO, ZYME, and XNCR

How does ProKidney compare to Sarepta Therapeutics?

Summary

How does ProKidney compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does ProKidney compare to Mesoblast?

Summary

How does ProKidney compare to Zymeworks?

Summary

How does ProKidney compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. SRPT, LKFT, MESO, ZYME, and XNCR

How does ProKidney compare to Sarepta Therapeutics?

Is PROK or SRPT more profitable?

Which has more risk & volatility, PROK or SRPT?

Do analysts rate PROK or SRPT?

Does the media favor PROK or SRPT?

Do insiders and institutionals believe in PROK or SRPT?

Which has preferable valuation and earnings, PROK or SRPT?

Summary

How does ProKidney compare to Lakefront Biotherapeutics American Depositary Shares?

Is LKFT or PROK more profitable?

Do analysts rate LKFT or PROK?

Which has more volatility & risk, LKFT or PROK?

Which has higher earnings and valuation, LKFT or PROK?

Does the media favor LKFT or PROK?

Do institutionals & insiders believe in LKFT or PROK?

Summary

How does ProKidney compare to Mesoblast?

Does the media refer more to PROK or MESO?

Which has higher valuation & earnings, PROK or MESO?

Do institutionals & insiders hold more shares of PROK or MESO?

Is PROK or MESO more profitable?

Which has more risk and volatility, PROK or MESO?

Do analysts prefer PROK or MESO?

Summary

How does ProKidney compare to Zymeworks?

Does the media refer more to PROK or ZYME?

Which has stronger valuation & earnings, PROK or ZYME?

Do analysts recommend PROK or ZYME?

Do insiders and institutionals have more ownership in PROK or ZYME?

Which has more volatility and risk, PROK or ZYME?

Is PROK or ZYME more profitable?

Summary

How does ProKidney compare to Xencor?

Do insiders & institutionals believe in XNCR or PROK?

Which has higher valuation and earnings, XNCR or PROK?

Which has more volatility and risk, XNCR or PROK?

Do analysts rate XNCR or PROK?

Is XNCR or PROK more profitable?

Does the media prefer XNCR or PROK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools